Pyelonephritis News and Research

RSS

Pyelonephritis is an ascending urinary tract infection that has reached the ''pyelum'' (pelvis) of the kidney (''nephros'' in Greek).

Researchers confirm that cranberry extract helps fight UTIs in breastfed children under age one

Researchers from the universities of Granada (Spain) and Kvopio (Finland) have confirmed that cranberry extract helps fighting urinary tract infections (UTIs) in breastfed babies under one year of age.

18 Jan 2016

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Researchers at The Medicines Company presented data from a multi-national cohort that demonstrates the mortality and morbidity, and poor outcomes, associated with current therapies in patients with infections due to carbapenem-resistant Enterobacteriaceae (CRE). The data from this analysis has guided the design of the company’s on-going clinical studies of its Phase 3 compound, CARBAVANCE® (meropenem/RPX7009) and was presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, CA.

22 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Women are more likely to suffer urinary tract infections, but men are more prone to be hospitalized

While women are far more likely to suffer urinary tract infections, men are more prone to be hospitalized for treatment, according to a study by Henry Ford Hospital urologists.

9 Oct 2013

One-week ciprofloxacin effective for pyelonephritis

Treatment for 7 days with the antibiotic ciprofloxacin is as effective at treating acute pyelonephritis in women as a 14-day regimen of the fluoroquinolone, with a similar safety profile, report Swedish researchers.

17 Aug 2012

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults.

16 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011

RPCs transplant appears to improve kidney structure and function in rat models

Transplanting autologous renal progenitor cells, into rat models with kidney damage from pyelonephritis - a type of urinary infection that has reached the kidney - has been found to improve kidney structure and function.

14 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

ESWL should be first choice for removing smaller kidney stones in distal ureter

Different techniques should be used to remove single stones that have become lodged in the distal ureter after being expelled by the kidney, depending on whether they are under or above one centimetre, according to the December issue of BJUI.

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone.

24 Sep 2010

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Patients fitted with long-term bladder catheters often face a potentially serious complication caused by a Gram-negative bacteria Proteus mirabilis that can colonize the catheters.

16 Sep 2010

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

Achaogen, a biopharmaceutical company discovering and developing innovative antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the award of a contract with The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

31 Aug 2010

Creator of California Tay-Sachs Disease Prevention Program among the honorees

A mere 40 years ago, parents didn't know they were carriers of the Tay-Sachs disease until after they'd given birth to a child with this fatal genetic disorder.

7 May 2010

Anti-microbial catheter to cut infection risk for dialysis patients

Medical experts at The University of Nottingham have shown that an innovative anti-microbial catheter could vastly improve treatment and the quality of life for many community-based dialysis patients.

24 Mar 2009